- Home
- ROIV vs H Comparison
ROIV vs H Comparison
Compare ROIV & H Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- H
- Stock Information
- Founded
- ROIV 2014
- H 1957
- Country
- ROIV United Kingdom
- H United States
- Employees
- ROIV 750
- H N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- H Hotels/Resorts
- Sector
- ROIV Health Care
- H Consumer Discretionary
- Exchange
- ROIV Nasdaq
- H Nasdaq
- Market Cap
- ROIV 14.1B
- H 13.9B
- IPO Year
- ROIV N/A
- H 2009
- Fundamental
- Price
- ROIV $20.73
- H $165.52
- Analyst Decision
- ROIV Strong Buy
- H Buy
- Analyst Count
- ROIV 8
- H 16
- Target Price
- ROIV $21.19
- H $159.56
- AVG Volume (30 Days)
- ROIV 8.4M
- H 1.1M
- Earning Date
- ROIV 11-10-2025
- H 11-06-2025
- Dividend Yield
- ROIV N/A
- H 0.37%
- EPS Growth
- ROIV N/A
- H N/A
- EPS
- ROIV N/A
- H N/A
- Revenue
- ROIV $20,329,000.00
- H $3,339,000,000.00
- Revenue This Year
- ROIV N/A
- H $121.54
- Revenue Next Year
- ROIV $320.50
- H $4.88
- P/E Ratio
- ROIV N/A
- H N/A
- Revenue Growth
- ROIV N/A
- H N/A
- 52 Week Low
- ROIV $8.73
- H $102.43
- 52 Week High
- ROIV $21.35
- H $168.20
- Technical
- Relative Strength Index (RSI)
- ROIV 67.12
- H 70.95
- Support Level
- ROIV $19.99
- H $147.10
- Resistance Level
- ROIV $20.99
- H $158.84
- Average True Range (ATR)
- ROIV 0.74
- H 4.92
- MACD
- ROIV -0.19
- H 1.40
- Stochastic Oscillator
- ROIV 59.94
- H 93.65
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 30 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.